Investigational drug · Phase 3
ASKC202
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ASKC202"
First trial start
2025
Aug 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASKC202", any sponsor or status.
Conditions studied
As listed on its trial records.
- EGFR Activating Mutation
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- MET Positive
- Locally Advanced or Metastatic NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ASKC202" as an intervention, largest first.
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCPivotal-lookingNot yet recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07897188 · 425 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 30, 2030
Drug: ASKC202; ASKC202 placebo and 6 more · For: EGFR Activating Mutation; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); MET Positive
Sites: Shanghai, China
- ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyPivotal-lookingRecruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07109531 · 286 participants (planned) · Start Aug 4, 2025 · Primary completion Oct 31, 2027
Drug: ASKC202+ Limertinib; Pemetrexed + Cisplatin /Carboplatin · For: Locally Advanced or Metastatic NSCLC
Sites: Shanghai, China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT05306132 · 150 participants (planned) · Start Aug 8, 2022 · Primary completion Dec 2026
Drug: ASKC202; ASK120067 · For: Advanced Solid Tumor
Sites: Zhengzhou, China; Changsha, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for EGFR Activating Mutation
- LimertinibPhase 33 trials
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- TY-9591Phase 33 trials
TYK Medicines, Inc · NSCLC, EGFR Activating Mutation, Brain Metastases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.